A new review has found that drugs designed to clear amyloid, a protein that builds up in the brains of people with Alzheimer’s, offer little or no noticeable benefit after 18 months.
That result cuts against years of hope around these medicines and reframes what patients may actually gain from them.
Evidence shows across trials
Across 17 placebo-controlled trials, 20,342 participants with mild memory problems or mild dementia received one of seven drugs or placebo.
Working through that evidence, Francesco Nonino at the IRCCS Institute of Neurological Sciences of Bologna, (ISNB) found effects too small for patients to feel.
That pattern held even though the review included the newer medicines already in U.S. clinics alongside older drugs that had failed.
Even so, the finding stops short of settling what any single drug can do, which is why the argument widens from here.
Significance of amyloid
These drugs target amyloid, sticky protein buildup linked to Alzheimer’s, because researchers long suspected it helped drive the disease.
Each antibody latches onto that protein and marks it for removal, engaging the brain’s cleanup cells to clear plaques.
Later, lecanemab, a drug that targets and removes amyloid buildup in the brain, and donanemab, a similar treatment designed to clear those protein deposits, each showed enough slowing to win U.S. approval in 2023 and 2024.
That history explains why a pooled verdict feels harsher than the story many patients heard when those approvals arrived.
Brain swelling and bleeding risks
Safety is where the review lands hardest, because these drugs increased amyloid-related imaging abnormalities, scan-detected swelling or bleeding in the brain.
When antibodies strip amyloid from blood vessel walls as well as plaques, fragile vessels can leak fluid or small amounts of blood.
At 18 months, the pooled review found 107 more cases of swelling per 1,000 treated people than placebo.
Most episodes seen on scans caused no obvious symptoms, but the authors said inconsistent reporting leaves the long-term consequences uncertain.
Measuring meaningful change
The sharpest point in the review is not that scores barely moved, but that the movement was likely negligible.
Public remarks from the review team made one issue unmistakable: small score changes are not always felt in daily life.
“Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients,” said Nonino.
Whether that definition of meaningful is too strict sits at the center of the backlash from some clinicians.
Controversy behind the conclusions
Critics say the pooled result blurs older failed antibodies with the two drugs now used in U.S. memory clinics.
By combining one lecanemab trial and one donanemab trial with many earlier failed drugs, the review ends up judging the whole group rather each singular drug.
“Existing approved drugs offer some benefit for some patients,” said Edo Richard, professor of neurology at Radboud University Medical Center.
Gaps in long-term data
The review also points to a basic problem in the evidence, because most trials lasted only about 18 months.
Alzheimer’s progresses slowly, so a short follow-up can miss later benefit or later harm.
Reporting also broke down on symptoms, making it clearer to the public what scans showed versus what patients felt.
That gap weakens both camps, because supporters and skeptics are still arguing over side effects that were not described well enough.
Cost and complexity of treatment
Even modest benefits would come with heavy logistics, because these medicines are given by infusion and demand repeated brain scans.
Doctors must confirm amyloid before treatment and keep watching for these changes, which means more appointments, staff time, and scanner access.
That burden hits unevenly, since trial populations were mostly homogenous and the monitoring structure favored health systems with vast resources.
A drug can be approved and still inaccessible to many families, hospitals, and public insurers.
Moving beyond amyloid
The review does not say Alzheimer’s is untreatable, only that amyloid removal alone has not delivered what patients need.
That conclusion focuses on other brain targets, including inflammation, the immune activity that can damage brain tissue.
Nonino said the field now needs other targets, not just better ways to remove the same protein.
Future drugs may still hit amyloid, but many researchers now expect combinations that tackle several processes at once.
Real-world treatment tradeoffs
None of this turns treatment choices into a simple yes or no, especially for people already taking these drugs.
Current patients face tradeoffs between small possible slowing, known monitoring demands, and a real chance of swelling or bleeding.
For some families, a modest delay still matters, while others may decide the clinic time and possible uncertainty.
That is why the most important lesson from this review may be honesty, not panic, during informed consent.
A narrow view of current drugs
The evidence now paints a narrow and uncomfortable picture: amyloid-clearing drugs can change brain biology without clearly changing life in ways patients notice.
Researchers will keep testing longer courses and new combinations, but clinicians already must explain that lower plaque counts are not better days.
The study is published in the journal Cochrane Database of Systematic Reviews.
—–
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
—–